Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020198517> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2020198517 endingPage "813" @default.
- W2020198517 startingPage "813" @default.
- W2020198517 abstract "Bevacizumab in the treatment of HER2-negative breast cancer Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination with cytotoxic treatment. Additionally, bevacizumab potentially increases the effectiveness of other anticancer therapies through the normalization of tumor vasculature, reduction of intratumoral pressure and improved tumor oxygenation. Phase 1/2 trials showed significant antitumor effects of bevacizumab in MBC, in particular in tumors not expressing HER2 receptor. A first phase 3 trial in pre-treated MBC patients showed better response rates but no survival benefit from the addition of bevacizumab to capecitabine. However, in two phase 2 trial in first-line setting in patients with MBC, bevacizumab improved progression-free survival in combination with weekly paclitaxel in comparison to paclitaxel alone or in combination with 3-weekly docetaxel in comparison with docetaxel alone, respectively. Bevacizumab in combination with taxanes seems to be a highly effective first-line treatment for MBC patients. Future research will investigate bevacizumab in the neoadjuvant or adjuvant setting, where even more potential may exist for these patients.Keywords: bevacizumab, breast cancer, HER2, HER2-negative breast cancer" @default.
- W2020198517 created "2016-06-24" @default.
- W2020198517 creator A5090055323 @default.
- W2020198517 date "2008-11-01" @default.
- W2020198517 modified "2023-09-26" @default.
- W2020198517 title "Bevacizumab in the treatment of HER2-negative breast cancer" @default.
- W2020198517 cites W156576096 @default.
- W2020198517 cites W1595263809 @default.
- W2020198517 cites W1596105818 @default.
- W2020198517 cites W161274711 @default.
- W2020198517 cites W1665704747 @default.
- W2020198517 cites W1886850372 @default.
- W2020198517 cites W1983505224 @default.
- W2020198517 cites W1984750597 @default.
- W2020198517 cites W1985712533 @default.
- W2020198517 cites W2006202974 @default.
- W2020198517 cites W2029008736 @default.
- W2020198517 cites W2050775025 @default.
- W2020198517 cites W2059860479 @default.
- W2020198517 cites W2068014745 @default.
- W2020198517 cites W2070264124 @default.
- W2020198517 cites W2086157929 @default.
- W2020198517 cites W2098114704 @default.
- W2020198517 cites W2104316189 @default.
- W2020198517 cites W2114159573 @default.
- W2020198517 cites W2117188579 @default.
- W2020198517 cites W2126275851 @default.
- W2020198517 cites W2130334661 @default.
- W2020198517 cites W2131705241 @default.
- W2020198517 cites W2145224595 @default.
- W2020198517 cites W2147913778 @default.
- W2020198517 cites W2150763257 @default.
- W2020198517 cites W2164242657 @default.
- W2020198517 cites W2169965478 @default.
- W2020198517 cites W2295734057 @default.
- W2020198517 cites W2597616474 @default.
- W2020198517 doi "https://doi.org/10.2147/btt.s3515" @default.
- W2020198517 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2727886" @default.
- W2020198517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19707460" @default.
- W2020198517 hasPublicationYear "2008" @default.
- W2020198517 type Work @default.
- W2020198517 sameAs 2020198517 @default.
- W2020198517 citedByCount "5" @default.
- W2020198517 countsByYear W20201985172016 @default.
- W2020198517 countsByYear W20201985172021 @default.
- W2020198517 crossrefType "journal-article" @default.
- W2020198517 hasAuthorship W2020198517A5090055323 @default.
- W2020198517 hasBestOaLocation W20201985171 @default.
- W2020198517 hasConcept C121608353 @default.
- W2020198517 hasConcept C126322002 @default.
- W2020198517 hasConcept C143998085 @default.
- W2020198517 hasConcept C167734588 @default.
- W2020198517 hasConcept C2775930923 @default.
- W2020198517 hasConcept C2776694085 @default.
- W2020198517 hasConcept C2776999253 @default.
- W2020198517 hasConcept C2777025900 @default.
- W2020198517 hasConcept C2777292972 @default.
- W2020198517 hasConcept C2777802072 @default.
- W2020198517 hasConcept C2777909004 @default.
- W2020198517 hasConcept C2781190966 @default.
- W2020198517 hasConcept C526805850 @default.
- W2020198517 hasConcept C530470458 @default.
- W2020198517 hasConcept C71924100 @default.
- W2020198517 hasConcept C98274493 @default.
- W2020198517 hasConceptScore W2020198517C121608353 @default.
- W2020198517 hasConceptScore W2020198517C126322002 @default.
- W2020198517 hasConceptScore W2020198517C143998085 @default.
- W2020198517 hasConceptScore W2020198517C167734588 @default.
- W2020198517 hasConceptScore W2020198517C2775930923 @default.
- W2020198517 hasConceptScore W2020198517C2776694085 @default.
- W2020198517 hasConceptScore W2020198517C2776999253 @default.
- W2020198517 hasConceptScore W2020198517C2777025900 @default.
- W2020198517 hasConceptScore W2020198517C2777292972 @default.
- W2020198517 hasConceptScore W2020198517C2777802072 @default.
- W2020198517 hasConceptScore W2020198517C2777909004 @default.
- W2020198517 hasConceptScore W2020198517C2781190966 @default.
- W2020198517 hasConceptScore W2020198517C526805850 @default.
- W2020198517 hasConceptScore W2020198517C530470458 @default.
- W2020198517 hasConceptScore W2020198517C71924100 @default.
- W2020198517 hasConceptScore W2020198517C98274493 @default.
- W2020198517 hasLocation W20201985171 @default.
- W2020198517 hasLocation W20201985172 @default.
- W2020198517 hasLocation W20201985173 @default.
- W2020198517 hasLocation W20201985174 @default.
- W2020198517 hasOpenAccess W2020198517 @default.
- W2020198517 hasPrimaryLocation W20201985171 @default.
- W2020198517 isParatext "false" @default.
- W2020198517 isRetracted "false" @default.
- W2020198517 magId "2020198517" @default.
- W2020198517 workType "article" @default.